Clinical trial
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
The primary objective is to test the hypothesis that, compared with placebo, therapy with Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge period will be associated with greater clinical stability at six months as assessed by a composite clinical endpoint.
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 300 |
| Study start date | 2013-04-01 |
| Estimated primary completion date | 2015-10-01 |